CASE LA0085 NP

9 JUN 0 1 2004

CERTIFICATE OF MAILING

Hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313'-1450.

Kathleen Bodine

Type or print name

een (dane

May 26, 2004

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG ET AL.

APPLICATION NO: 10/616,283

FILED: JULY 8, 2003

FOR: SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS

ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD

Mail Stop Box Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: May 26, 2004

Respectfully submitted,

Burton Rodney Attorney for Applicants

Reg. No. 22,076

23914

PATENT TRADEMARK OFFICE



CERTIFICATE OF MAILING

Thereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA,22313-1450.

Kathleen Bodine

Type or print name

auteen Ordine)

May 26, 2004

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG ET AL.

APPLICATION NO: 10/616,283

FILED: JULY 8, 2003

FOR: SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS

ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD

Mail Stop Box Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

06/03/2004 BABRAHA1 00000067 193880 10616283

01 FC:1806 180.00 DA

23914

PATENT TRADEMARK OFFICE

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: May 26, 2004

Respectfully submitted,

Burton Rodney Attorney for Applicants Reg. No. 22,076 FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0085 NP APPLICATION NO. 10/616,283 APPLICANT CHENG ET AL. FILING DATE JULY 8, 2003

Group

U.S. PATENT DOCUMENTS

| | | | 0.0.1 | PATENT DOCUMENTS | | | | |
|---------------------|----|-----------------|----------|--------------------------------------|---------------|----------|-----|----------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLA | SUBCLA | ss | FILING DATE |
| | AA | 6,506,781 | 1/14/03 | Cobb et al. | | | | |
| | AB | 6,653,314 | 11/25/03 | Cheng et al. | | , | | |
| | AC | | , | | | | | |
| | AD | | - | | | | | |
| | ΑE | | | | | | | |
| | AF | | | | | | | |
| | AG | | | | | | Î | |
| | АН | | | | | | | - |
| 0.00 | Al | | | | | | | |
| , | AJ | | | | | | | |
| | AK | | | | | | | |
| ··· | AL | | | | | | | |
| <u>-</u> | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRA | NSLATION NO |
| | АМ | | | | | | | |
| | AN | | | | | | | |
| | AO | | | | | | | |
| • | AP | | | | | | | |
| | AQ | | | | | (| | |
| | | OTHER DOC | UMENTS (| Including Author, Title, Date, Perti | nent pages, E | tc.) | | |
| | | | | | | | | |
| | AR | | | | | | | |
| | AS | | | | | | | |
| | AT | | | | | | | |
| EXAMIN | | | | DATE CONSIDERED | | | | |

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.